Clinical Trial Update: Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody [Phase 1]

View source ↗

Summary

Phase 1 trial comparing two formulations of the CP-675,206 monoclonal antibody for melanoma has completed, sponsored by AstraZeneca.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• CP-675,206 monoclonal antibody (CP-675,206)

Snippet

Sponsor: AstraZeneca | Conditions: Melanoma | Phase 1 | Status: COMPLETED